Mexico City, Mexico — The pharmaceutical industry announces a 12.2 billion peso investment in Mexico. The Ministry of Economy and the Ministry of Health announced as part of Plan Mexico, an investment of 12.2 billion pesos by four companies in the pharmaceutical industry.
Those companies include Boehringer Ingelheim with an investment of 3.5 billion pesos, Carnot Laboratories also with 3.5 billion pesos, Bayer with a 3 billion peso investment and AstraZeneca with 2.25 billion.
President Claudia Sheinbaum says the investments will generate 3,120 highly specialized direct jobs and 22,500 indirect jobs. She also reported that the first Economic Development Pole for Well-being “Parque Industrial Bajío,” is being established in Zinapécuaro, Michoacán, covering 346 hectares.
It already has its first investors, Citelis and Artifibras. This represents a public-private investment of more than 1 billion pesos in its initial phase.
President Sheinbaum emphasized that the investment announcement demonstrates that Plan Mexico is moving forward and kick-starts the drive for development and well-being throughout the country.
“A very significant investment of 12 billion pesos from the pharmaceutical industry for production and research development in our country, linked to the pharmaceutical industry, is part of Plan Mexico, as we proposed.
“At the same time, I am very pleased to announce the first Development Hub for Well-being in Michoacán, which already has committed investors and is already beginning this phase of promoting Development with Well-being in our country.”
Mexico’s Secretary of Economy Marcelo Ebrard Casaubon described the 12 billion peso investment in the pharmaceutical sector as significant, as it is a top priority for the President given its impact on the health of the Mexican population.
Mexico’s Health Secretary David Kershenobich Stalnikowitz explained that the investment by the four pharmaceutical companies will generate more than 3,000 direct jobs and 20,000 indirect jobs. He noted that the health sector is experiencing a period of transformation, as innovation is fostered, clinical research capabilities are expanded and processes are digitized.
The president of the National Chamber of the Pharmaceutical Industry (Canifarma), Guillermo Funes Rodríguez, acknowledged that they are surprised by the progress made by the Federal Commission for the Protection against Sanitary Risks (Cofepris), as it will allow for more research and, together with the Secretariat of Science, Humanities, Technology and Innovation (Secihti), the development of specific medium- and long-term projects for the benefit of the Mexican population.
Bayer Mexico CEO Manuel Bravo Pereyra, stated that the 3 billion peso investment over the next five years will be used to expand the production capacity of active pharmaceutical ingredients at its plant in Orizaba, Veracruz.
It will also add more production lines for new medicines in Lerma, State of Mexico and to double the production capacity of biological fungicides at its factory located in Tlaxcala, which exports to more than 100 countries around the world.
He also highlighted that the investment in Mexico is thanks to national talent, the advantage through the USMCA that provides access to the Mexican and North American markets and the legal certainty that exists in the country.
Juan Augusto Muench Castañeda, the General Director of Boehringer Ingelheim for Mexico, Central America and the Caribbean, reported that the 3.5 billion pesos that his company will invest will be multiannual to make its plant in Xochimilco the largest in the world with the production of 5 thousand pharmaceutical tablets to supply the local market and export to more than 40 countries.
The General Director of Laboratorios Carnot, Edmundo Jiménez Luna, stated that the investment of 3.5 billion pesos will be used to build a new plant in Villa de Tezontepec, Hidalgo, and will generate 600 direct jobs and 5,000 indirect jobs.
AstraZeneca Mexico’s CEO, Julio Ordaz, explained that the 2.25 billion peso investment will be made over the next two years dedicated to clinical research, the expansion of its Global Innovation and Technology Center, as well as the expansion of its factory in the State of Mexico, thereby generating 600 direct jobs and 2,500 indirect jobs.
Michoacán Governor Alfredo Ramírez Bedolla, accompanied by Eduardo Ramírez Díaz, CEO of Citelis, and David Martínez Gómez Tagle, CEO of Artifibras, emphasized that the Bajío Industrial Park will make the state a leading international logistics hub thanks to its excellent connectivity via rail, the Lázaro Cárdenas port, the Western Highway and Morelia International Airport.
In may, President Sheinbaum announced that a decree would be published in the Official Gazette of the Federation (DOF) to encourage international pharmaceutical companies to invest in projects for the production of medicines and medical supplies in Mexico next year.
The goal, she said at the time, is to position Mexico as a leader in the pharmaceutical industry.
